ArticleJACC. Case reports2026
Subacute Stent Thrombosis Associated With Prasugrel Refractoriness in a Patient With Chronic ITP.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo our knowledge, there have been no reports of stent thrombosis due to prasugrel nonresponse in patients with immune thrombocytopenia (ITP). CASE SUMMARY: A 66-year-old man with chronic ITP presented with an inferior ST-segment elevation myocardial infarction. The patient underwent drug-eluting stent implantation. On the sixth day, he developed recurrent chest pain. Coronary angiography revealed subacute stent thrombosis. P2Y DISCUSSION: This case demonstrates that stent thrombosis can occur in patients unresponsive to prasugrel and that PRU measurement may be useful even in ITP patients. TAKE-HOME MESSAGES: In ITP patients, it is necessary to carefully balance the risk of thrombosis with the risk of bleeding. Prasugrel nonresponse may contribute to stent thrombosis, and PRU may be useful for identifying prasugrel nonresponse in patients with ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.